Search Results - "West, Rachel L"

Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study by Straatmijer, Tessa, Biemans, Vince B C, Hoentjen, Frank, de Boer, Nanne K H, Bodelier, Alexander G L, Dijkstra, Gerard, van Dop, Willemijn A, Haans, Jeoffrey J L, Jansen, Jeroen M, Maljaars, P W Jeroen, van der Marel, Sander, Oldenburg, Bas, Ponsioen, Cyriel Y, Visschedijk, Marijn C, de Vries, Annemarie C, West, Rachel L, van der Woude, C Janneke, Pierik, Marieke, Duijvestein, Marjolijn, van der Meulen-de Jong, Andrea E

“…Abstract Aims Ustekinumab is a monoclonal antibody that selectively targets p40, a shared subunit of the cytokines interleukin [IL]-12 and IL-23. It is…”
Get full text

Health State Questionnaires Deployed in Ulcerative Colitis Patients: The Medical, Psychological, and Economic Perspective by Broekharst, Damien S.E., Thomas, Pepijn W.A., Russel, Maurice G.V.M., West, Rachel L., Jansen, Jeroen M., Bloem, Sjaak, Römkens, Tessa E.H.

“…To determine how the health state of ulcerative colitis patients is impacted by their disease, different health state questionnaires are deployed. This study…”
Get full text

Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options by Bourgonje, Arno R., van Linschoten, Reinier C. A., West, Rachel L., van Dijk, Maarten A., van Leer-Buter, Coretta C., Kats-Ugurlu, Gursah, Pierik, Marieke J., Festen, Eleonora A. M., Weersma, Rinse K., Dijkstra, Gerard

“…In the wake of the coronavirus disease 2019 (COVID-19) pandemic, it is unclear how asymptomatic severe acute respiratory syndrome coronavirus-2…”
Get full text

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment by Biemans, Vince B. C., Woude, C. Janneke, Dijkstra, Gerard, Meulen‐de Jong, Andrea E., Löwenberg, Mark, Boer, Nanne K., Oldenburg, Bas, Srivastava, Nidhi, Jansen, Jeroen M., Bodelier, Alexander G. L., West, Rachel L., Vries, Annemarie C., Haans, Jeoffrey J. L., Jong, Dirk, Hoentjen, Frank, Pierik, Marieke J.

“…Summary Background Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However,…”
Get full text

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease by Binkhorst, Lisette, Sobels, Annemieke, Stuyt, Rogier, Westerman, Elsbeth M, West, Rachel L

“…OBJECTIVECurrently, a biosimilar of Remicade is available (CT-P13). Switching patients from Remicade to a biosimilar is still under debate, especially for…”
Get full text

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn’s disease by ten Bokkel Huinink, Sebastiaan, Biemans, Vince, Duijvestein, Marjolijn, Pierik, Marieke, Hoentjen, Frank, West, Rachel L., van der Woude, Christien J., de Vries, Annemarie C.

“…Re-induction with intravenous ustekinumab after secondary loss of response in Crohn's disease is a relatively new strategy to regain efficacy. This real-world…”
Get full text

High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease by San, Esma H., Egberts, Angelique, van Dijck - van Boetzelaer, Caroline W. Th, West, Rachel L., Vasbinder, Erwin C.

“…Purpose Adalimumab has evolved to one of the more affordable first-line biologics for the treatment of inflammatory bowel disease (IBD), since its patent…”
Get full text

A comparative analysis of tioguanine versus low‐dose thiopurines combined with allopurinol in inflammatory bowel disease patients by Biemans, Vince B. C., Savelkoul, Edo, Gabriëls, Ruben Y., Simsek, Melek, Dijkstra, Gerard, Pierik, Marieke J., West, Rachel L., Boer, Nanne K.H., Hoentjen, Frank

“…Summary Background Both tioguanine and low‐dose thiopurines combined with allopurinol (LDTA) can be considered for the treatment of inflammatory bowel disease…”
Get full text

Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study by Thomas, Pepijn W A, den Broeder, Nathan, Derikx, Monique, Kievit, Wietske, West, Rachel L, Russel, Maurice G V M, Jansen, Jeroen M, Römkens, Tessa E H, Hoentjen, Frank

“…There are limited real-world data on the change in total work impairment (TWI) in biological-treated patients with inflammatory bowel disease (IBD). This study…”
Get full text

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study by Asscher, Vera E. R., Biemans, Vince B. C., Pierik, Marieke J., Dijkstra, Gerard, Löwenberg, Mark, Marel, Sander, Boer, Nanne K. H., Bodelier, Alexander G. L., Jansen, Jeroen M., West, Rachel L., Haans, Jeoffrey J. L., Dop, Willemijn A., Weersma, Rinse K., Hoentjen, Frank, Maljaars, P. W. Jeroen

“…Summary Background Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel…”
Get full text

Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab by Biemans, Vince B C, van der Woude, C Janneke, Dijkstra, Gerard, van der Meulen-de Jong, Andrea E, Oldenburg, Bas, de Boer, Nanne K, Löwenberg, Mark, Srivastava, Nidhi, Bodelier, Alexander G L, West, Rachel L, Jansen, Jeroen M, de Vries, Annemarie C, Haans, Jeoffrey J L, de Jong, Dirk J, Pierik, Marie J, Hoentjen, Frank

“…Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical…”
Get full text

Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease by de Jong, Michiel E., Taal, Erik, Thomas, Pepijn W. A., Römkens, Tessa E. H., Jansen, Jeroen M., West, Rachel L., Slotman, Ellen, Hoentjen, Frank, Russel, Maurice G. V. M.

“…There is a need for easy-to-use patient-reported outcome measures (PROMS) in inflammatory bowel disease (IBD) practice. The 'IBD-control' is a short…”
Get full text

Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study by van Linschoten, Reinier C A, van der Woude, C Janneke, Visser, Elyke, van Leeuwen, Nikki, Bodelier, Alexander G L, Fitzpatrick, Claire, de Jonge, Vincent, Vermeulen, Hestia, Verweij, K Evelyne, van der Wiel, Sanne, Nieboer, Daan, Birnie, Erwin, van der Horst, Daniëlle, Hazelzet, Jan A, van Noord, Desirée, West, Rachel L

“…Data on variation in outcomes and costs of the treatment of inflammatory bowel disease (IBD) can be used to identify areas for cost and quality improvement. It…”
Get full text

Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study by Thomas, Pepijn W.A., van Caem, Mark, West, Rachel L., Russel, Maurice G.V.M, Jansen, Jeroen M., Römkens, Tessa E.H., Hoentjen, Frank

“…Real-world data showed that ustekinumab is an effective treatment for Crohn's disease for up to 52 weeks. Yet, long-term effectiveness and safety outcomes…”
Get full text

Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease by Binkhorst, Lisette, Sobels, Annemieke, Stuyt, Rogier, Westerman, Elsbeth M, West, Rachel L

“…Currently, a biosimilar of Remicade is available (CT-P13). Switching patients from Remicade to a biosimilar is still under debate, especially for patients with…”
Get full text

Patients with immune mediated inflammatory diseases are insufficiently protected against vaccine-preventable infections by van de Pol, Natasja, van der Woude, C Janneke, Vis, Marijn, van Doorn, Martijn B A, Schrauwen, Saskia L, Cetinözman-Teunissen, Fatos, West, Rachel L, de Vries, Annemarie C

“…Patients with Immune Mediated Inflammatory Diseases (IMIDs) using immunosuppressive therapy are at increased risk of infections, including vaccine-preventable…”
Get full text

Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study by Derikx, Lauranne A A P, Lantinga, Marten A, de Jong, Dirk J, van Dop, Willemijn A, Creemers, Rob H, Römkens, Tessa E H, Jansen, Jeroen M, Mahmmod, Nofel, West, Rachel L, Tan, Adriaan C I T L, Bodelier, Alexander G L, Gorter, Moniek H P, Boekema, Paul J, Halet, Eric R C, Horjus, Carmen S, van Dijk, Maarten A, Hirdes, Meike M C, Epping Stippel, Ludger S M, Jharap, Bindia, Lutgens, Maurice W M D, Russel, Maurice G, Gilissen, Lennard P L, Nauta, Sjoukje, van Bodegraven, Adriaan A, Hoentjen, Frank

“…Abstract Background and Aims The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess…”
Get full text

No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis by Lie, Mitchell R.K. L., Kreijne, Joany E., Dijkstra, Gerard, Löwenberg, Mark, van Assche, Gert, West, Rachel L., van Noord, Desiree, van der Meulen - de Jong, Andrea E., Oldenburg, Bas, Zaal, Rianne J., Hansen, Bettina E., de Vries, Annemarie C., Janneke van der Woude, Christien

“…Ulcerative proctitis (UP) refractory to 5-aminosalicylic acid (5-ASA) suppositories is a challenge to treat, often requiring step up to immunomodulator or…”
Get full text

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry by Straatmijer, Tessa, Schaik, Fiona D. M., Bodelier, Alexander G. L., Visschedijk, Marijn, Vries, Annemarie C., Ponsioen, Cyriel Y., Pierik, Marieke, Bodegraven, Ad A., West, Rachel L., Boer, Nanne K. H., Srivastava, Nidhi, Romkens, Tessa E. H., Hoekstra, Jildou, Oldenburg, Bas, Dijkstra, Gerard, Woude, Janneke C., Löwenberg, Mark, Mujagic, Zlatan, Biemans, Vince B. C., Meulen‐de Jong, Andrea E., Duijvestein, Marjolijn

“…Summary Background Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of…”
Get full text

Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry by Giraud, Eline L., Thomas, Pepijn W. A., van Lint, Jette A., van Puijenbroek, Eugene P., Römkens, Tessa E. H., West, Rachel L., Russel, Maurice G. V. M., Jansen, Jeroen M., Jessurun, Naomi T., Hoentjen, Frank

“…Introduction Inflammatory bowel disease (IBD) frequently requires chronic immunosuppressive treatment and active involvement from patients during treatment…”
Get full text